Abstract
to 12.5% in the gemcitabine group with statistically significant difference (P 0.05) and urinary frequency was present in 45% of the BCG group compared to 10% in the gemcitabine group with highly significant statistical difference (P 0.001). CONCLUSIONS: After complete TUR-BT, at short term follow up, intravesical Gemcitabine was as effective as BCG in prevention of recurrence and progression of non-muscle invasive TCC of the bladder, even with a better safety profile and minimal toxicity. Further studies are needed to confirm these findings in a large number of patients with a longer follow up period.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have